Table 3. Treatment received, response and evolution of patients with a diagnosis of Lymphoproliferative Disease associated with renal transplantation .
| Case | Immuno-suppression* | Immuno-suppression† | PTLD Treatment | Tumor Response | Follow-up time (months) | Death |
|---|---|---|---|---|---|---|
| 1 | Tac,-MMF-Pred | Syr-MMF, pred | Rituximab x 5 weeks | Partial remission | 32 | No |
| 2 | Tac-Aza-Pred | Eve-pred | Rituximab x 2 weeks ABVD x 2 | Partial remission | 46 | No |
| 3 | CsA-MMF-Pre | Eve-MMF-Pred | Rituximab x 4 weeks | Complete remission | 48 | No |
| 4 | CsA-MMF-Pre | Syr-Pred | Rituximab x 4 weeks CDE infusion modified x 1 | Complete remission, Relapse | 17 | Yes, secondary to sepsis of pulmonary origin |
| 5 | CsA-MMF-Pre | None | Rituximab x 4 weeks + R-CHOP x 1 | Partial response | 36 | No |
| 6 | CsA-MMF-Pre | Syr-Pred | Rituximab x 4 weeks | Complete remission, Relapse | 70 | No |
| 7 | Tac-Aza-Pred | Eve-Pred | Rituximab x 4 weeks | Complete remission | 32 | N |
| 8 | CsA-MMF-Pre | Syr-Pred | Rituximab x 4 weeks + CHOP x 4 cycles | Complete remission | 28 | No |
*Immunosuppression at PTLD diagnosis
†Immunosuppression posterior to PTLD diagnosis.
Tac: Tacrolimus, MMF: Mofetil mycophenolate, Aza: Azathioprine, Pred: Prednisolone, CSA: Cyclosporin, Syr: sirolimus, Eve: everolimus, CHOP: Cyclophosphamide, doxorubicin, vincristine, prednisolone, CDE: Cyclophosphamide, doxorubicin (-), etopoxide, ABVD: Doxorubicin, bleomycin, vincristine, dacarbazine.